Patents by Inventor Russell D. Cink

Russell D. Cink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENZYMATIC PROCESSES FOR THE PREPARATION OF (±)-2-(DIFLUOROMETHYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID AND (±)-2-(VINYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID
    Publication number: 20210087592
    Abstract: Disclosed are methods of synthesizing racemic 2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and 2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and their salts, such as the dicyclohexylamine salt. Also disclosed are methods for preparing enantioenriched (1R,2R)-1-((tert-butoxycarbonyl)amino)-2-(difluoromethyl)cyclopropane-1-carboxylic acid and esters of the same. These compounds are useful intermediates in the synthesis of viral protease inhibitors.
    Type: Application
    Filed: May 11, 2020
    Publication date: March 25, 2021
    Inventors: Michael J. Abrahamson, Sanjay R. Chemburkar, Angelica B. Kielbus, Russell D. Cink
  • Enzymatic processes for the preparation of (±)-2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid and (±)-2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid
    Patent number: 10689675
    Abstract: Disclosed are methods of synthesizing racemic 2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and 2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and their salts, such as the dicyclohexylamine salt. Also disclosed are methods for preparing enantioenriched (1R,2R)-1-((tert-butoxycarbonyl)amino)-2-(difluoromethyl)cyclopropane-1-carboxylic acid and esters of the same. These compounds are useful intermediates in the synthesis of viral protease inhibitors.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: June 23, 2020
    Assignee: AbbVie Inc.
    Inventors: Michael J. Abrahamson, Sanjay R. Chemburkar, Angelica B. Kielbus, Russell D. Cink
  • SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS
    Publication number: 20200095230
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Application
    Filed: September 27, 2019
    Publication date: March 26, 2020
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Synthetic route to anti-viral agents
    Patent number: 10442792
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: October 15, 2019
    Assignee: AbbVie Inc.
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS
    Publication number: 20190084966
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Application
    Filed: September 17, 2018
    Publication date: March 21, 2019
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Synthetic route to anti-viral agents
    Patent number: 10077256
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: September 18, 2018
    Assignee: AbbVie Inc.
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • ENZYMATIC PROCESSES FOR THE PREPARATION OF (±)-2-(DIFLUOROMETHYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID AND (±)-2-(VINYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID
    Publication number: 20180258451
    Abstract: Disclosed are methods of synthesizing racemic 2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and 2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and their salts, such as the dicyclohexylamine salt. Also disclosed are methods for preparing enantioenriched (1R,2R)-1-((tert-butoxycarbonyl)amino)-2-(difluoromethyl)cyclopropane-1-carboxylic acid and esters of the same. These compounds are useful intermediates in the synthesis of viral protease inhibitors.
    Type: Application
    Filed: February 1, 2018
    Publication date: September 13, 2018
    Inventors: Michael J. Abrahamson, Sanjay R. Chemburkar, Angelica B. Kielbus, Russell D. Cink
  • SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS
    Publication number: 20180057482
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Application
    Filed: November 6, 2017
    Publication date: March 1, 2018
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Synthetic route to anti-viral agents
    Patent number: 9809576
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: November 7, 2017
    Assignee: AbbVie Inc.
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Macrocyclic hepatitis C serine protease inhibitors
    Patent number: 9493506
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: November 15, 2016
    Assignees: AbbVie Inc., Enata Pharmacueticals, Inc.
    Inventors: Hui-Ju Chen, Keith F. McDaniel, Brian E. Green, Jason P. Shanley, Albert W. Kruger, Jorge Gandarilla, Dennie S. Welch, Russell D. Cink, Steven C. Cullen, Yonghua Gai, Guoqiang Wang, Yat Sun Or
  • MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20140287992
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: June 9, 2014
    Publication date: September 25, 2014
    Inventors: Hui-Ju Chen, Keith F. McDaniel, Brian E. Green, Jason P. Shanley, Albert W. Kruger, Jorge Gandarilla, Dennie S. Welch, Russell D. Cink, Steven C. Cullen, Yonghua Gai, Guoqiang Wang, Yat Sun Or
  • Macrocyclic hepatitis C serine protease inhibitors
    Patent number: 8748374
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: June 10, 2014
    Assignee: AbbVie, Inc.
    Inventors: Hui-Ju Chen, Keith F. McDaniel, Brian E. Green, Jason P. Shanley, Albert W. Kruger, Jorge Gandarllla, Dennie S. Welch, Russell D. Cink, Steven C. Cullen, Yonghua Gai, Guoqiang Wang, Yat Sun Or
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8487116
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 16, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Chih-Hung Lee, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
    Publication number: 20120190845
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Application
    Filed: November 9, 2011
    Publication date: July 26, 2012
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chamboumier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20120101031
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: June 7, 2011
    Publication date: April 26, 2012
    Applicants: ENANTA PHARMACEUTICALS, INC., ABBOTT LABORATORIES
    Inventors: Hui-Ju Chen, Keith F. McDaniel, Brian E. Green, Jason P. Shanley, Albert W. Kruger, Jorge Gandarilla, Dennie S. Welch, Russell D. Cink, Steven C. Cullen, Yonghua Gai, Guoqiang Wang, Yat Sun Or
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8071762
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: December 6, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Marvin R. Leanna, Russell D. Cink
  • SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF
    Publication number: 20090263477
    Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
    Type: Application
    Filed: June 23, 2009
    Publication date: October 22, 2009
    Applicants: ABBOTT LABORATORIES, FOURNIER LABORATORIES IRELAND LTD
    Inventors: Russell D. Cink, Joseph B. Paterson, Yi Gao, Geoff G. Z. Zhang, Michelle A. Long, John B. Morris, Joerg Rosenberg
  • Anti-infective agents
    Patent number: 7538105
    Abstract: Compounds having the formula are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: May 26, 2009
    Assignee: Abbott Laboratories
    Inventors: Douglas K. Hutchinson, John R. Bellettini, David A. Betebenner, Richard D. Bishop, Thomas B. Borchardt, Todd D. Bosse, Russell D. Cink, Charles A. Flentge, Bradley D. Gates, Brian E. Green, Mira M. Hinman, Peggy P. Huang, Larry L. Klein, Allan C. Krueger, Daniel P. Larson, M. Robert Leanna, Dachun Liu, Darold L. Madigan, Keith F. McDaniel, John T. Randolph, Todd W. Rockway, Teresa A. Rosenberg, Kent D. Stewart, Vincent S. Stoll, Rolf Wagner, Ming C. Yeung
  • FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
    Publication number: 20080287676
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Application
    Filed: April 30, 2008
    Publication date: November 20, 2008
    Applicant: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • Anti-Infective Agents
    Publication number: 20080193413
    Abstract: Compounds having the formula are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
    Type: Application
    Filed: April 4, 2008
    Publication date: August 14, 2008
    Applicant: ABBOTT LABORATORIES
    Inventors: Douglas K. Hutchinson, John R. Bellettini, David A. Betebenner, Richard D. Bishop, Thomas B. Borchardt, Todd D. Bosse, Russell D. Cink, Charles A. Flentge, Bradley D. Gates, Brian E. Green, Mira M. Hinman, Peggy P. Huang, Larry L. Klein, Allan C. Krueger, Daniel P. Larson, M. Robert Leanna, Dachun Liu, Darold L. Madigan, Keith F. McDaniel, John T. Randolph, Todd W. Rockway, Teresa A. Rosenberg, Kent D. Stewart, Vincent S. Stoll, Rolf Wagner, Ming C. Yeung